NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines
Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclona...
Saved in:
Main Authors: | Luis E. Fernandez, Mariano R. Gabri, Marcelo D. Guthmann, Roberto E. Gomez, Silvia Gold, Leonardo Fainboim, Daniel E. Gomez, Daniel F. Alonso |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2010/814397 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer
by: Alejandra M. Scursoni, et al.
Published: (2011-01-01) -
GM1 Ganglioside Promotes Osteogenic Differentiation of Human Tendon Stem Cells
by: Sonia Bergante, et al.
Published: (2018-01-01) -
Elevation of ganglioside degradation pathway drives GM2 and GM3 within amyloid plaques in a transgenic mouse model of Alzheimer's disease
by: Wenxuan Wang, et al.
Published: (2025-02-01) -
The Multiple Extended Tidal Tails of NGC 288
by: Carl J. Grillmair
Published: (2025-01-01) -
Dietary Ganglioside Reduces Proinflammatory Signaling in the Intestine
by: John Janez Miklavcic, et al.
Published: (2012-01-01)